Astrazeneca Pharma India Ltd - Stock Valuation and Financial Performance

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Small Cap

Astrazeneca Pharma I Share Price

5,271 -48.75 -0.92%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Astrazeneca Pharma I

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Astrazeneca Pharma India stock performance -

mw4me loader
P/E Ratio (SA):
95.48
Market Cap:
13,301 Cr.
52-wk low:
3,102
52-wk high:
7,208

Is Astrazeneca Pharma India Ltd an attractive stock to invest in?

1. Is Astrazeneca Pharma India Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Astrazeneca Pharma India Ltd is a average quality company.

2. Is Astrazeneca Pharma India Ltd undervalued or overvalued?

The key valuation ratios of Astrazeneca Pharma India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Astrazeneca Pharma India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Astrazeneca Pharma India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Astrazeneca Pharma I:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -9.6%-13%3.6%7.8%11.1%19.7%22%22.7%12.5%22.9%-
Value Creation
Index
-1.7-1.9-0.8-0.4-0.20.40.60.7-0.10.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4745175645445717288328148061,0031,197
Sales YoY Gr.-9.1%9%-3.6%5%27.6%14.2%-2.2%-1%24.5%-
Adj EPS -5.2-8.42.25.910.521.628.936.923.950.255.7
YoY Gr.-NANA171.6%76.5%106.5%34.1%27.4%-35.2%110.1%-
BVPS (₹) 68.660.362.488.597.9119.5145.1181.8203.8234.5268.3
Adj Net
Profit
-13-215.514.826.15472.392.259.7126139
Cash Flow from Ops. -0.8-45.75738.18.85587.410510158.3-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.7%11.9%6.4%24.5%
Adj EPS NA36.9%20.2%110.1%
BVPS14.6%19.1%17.3%15.1%
Share Price 16.9% 21.4% 19.8% 63.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-9.6-133.67.811.119.721.722.512.322.822.2
Op. Profit
Mgn %
-2.8-2.636.98.29.814.616.710.716.516.3
Net Profit
Mgn %
-2.8-4.112.74.67.48.711.37.412.511.6
Debt to
Equity
0000000000-
Working Cap
Days
155173167185216176167193200185135
Cash Conv.
Cycle
17111711120-2-16473

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 22.20%

Net Profit is growing at healthy rate in last 3 years 20.17%

Sales growth is good in last 4 quarters at 26.02%

Sales growth has been subdued in last 3 years 6.44%

Latest Financials - Astrazeneca Pharma India Ltd.

Standalone Consolidated
TTM EPS (₹) 55.7 -
TTM Sales (₹ Cr.) 1,197 -
BVPS (₹.) 268.3 -
Reserves (₹ Cr.) 666 -
P/BV 19.83 -
PE 95.48 -
From the Market
52 Week Low / High (₹) 3102.00 / 7208.00
All Time Low / High (₹) 9.00 / 7208.00
Market Cap (₹ Cr.) 13,301
Equity (₹ Cr.) 5
Face Value (₹) 2
Industry PE 48.2

Management X-Ray of Astrazeneca Pharma I:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Astrazeneca Pharma I

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales4745175645445717288328148061,003
Operating Expenses 487531547507525657711678719838
Manufacturing Costs45263344595849576582
Material Costs155194195171178227300287305355
Employee Cost 160160169162150197217220230259
Other Costs 127150150129137175146115119142
Operating Profit -13-141637467112113586165
Operating Profit Margin (%) -2.8%-2.6%2.9%6.8%8.1%9.8%14.5%16.7%10.7%16.5%
Other Income 108714121613131526
Interest 0000001111
Depreciation 10151716151519201716
Exceptional Items 1400000000-40
Profit Before Tax 0-21636447311412783134
Tax 10115181842342135
Profit After Tax -1-21520265472936299
PAT Margin (%) -0.1%-4.0%0.9%3.7%4.5%7.5%8.7%11.5%7.6%9.9%
Adjusted EPS (₹)-0.2-8.32.18.010.421.828.937.324.639.7
Dividend Payout Ratio (%)0%0%0%0%0%0%3%5%41%40%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 172151156221245299363455509586
Share Capital 5555555555
Reserves 167146151216240294358450504581
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables1101119588127168210178190228
Others Liabilities 134150178205203124203241277328
Total Liabilities 4164124295145755917768749771,142

Fixed Assets

Gross Block170191204103106120133160169179
Accumulated Depreciation7690106163045617994110
Net Fixed Assets941019787757572817469
CWIP 912654724421
Investments 0000000000
Inventories96867758113118165160140190
Trade Receivables534383435580838586108
Cash Equivalents 892577116126173253352448500
Others Assets7414489206203138179192226274
Total Assets 4164124295145755917768749771,142

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity -1-4657389558710510158
PBT 0-21636447311412783134
Adjustment -119121538101410-5
Changes in Working Capital 18-3342-0-3410-3-433-30
Tax Paid -8-1-3-12-4-35-34-33-25-41
Cash Flow From Investing Activity -15-19-40-94-171173518
Capex -18-24-9-5-6-18-14-5-6-5
Net Investments 0000-1112-16916900
Others 45568111291123
Cash Flow From Financing Activity 860-1000-6-9-9-24
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 000000-1-1-1-1
Dividend Paid 000000-3-5-5-20
Others 8600000-3-3-4-4
Net Cash Flow 71-645338-159-902699652
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)-0.38-12.933.4310.6311.1220.0321.8322.8312.7818.13
ROCE (%)0-12.933.7618.7418.6526.5334.6131.2417.3624.49
Asset Turnover Ratio1.341.271.361.161.051.251.220.990.870.95
PAT to CFO Conversion(x)N/AN/A11.41.90.351.021.211.131.630.59
Working Capital Days
Receivable Days31334042313436383935
Inventory Days68635245555862736860
Payable Days236208193194220238230247220215

Astrazeneca Pharma India Ltd Stock News

Astrazeneca Pharma India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Astrazeneca Pharma I on 28-Mar-2024 16:01 is ₹5,271.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Astrazeneca Pharma I stood at ₹13,301.
The latest P/E ratio of Astrazeneca Pharma I as of 28-Mar-2024 16:01 is 95.48.
The latest P/B ratio of Astrazeneca Pharma I as of 28-Mar-2024 16:01 is 19.83.
The 52-week high of Astrazeneca Pharma I is ₹7,208 and the 52-week low is ₹3,102.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astrazeneca Pharma I is ₹1,197 ( Cr.) .

About Astrazeneca Pharma India Ltd

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.